Belly Fat

[PimpnAintEasy]

THE ANAVAR STUDIES SHOW reduction of VISCERAL FAT, not SUB Q.

This is true, also visceral fat, although primarily found in the abdominal region, is also found around the heart & lungs, and other organs. Part of what Anavar (& Tren for that matter) does is create muscular gains without a gain in visceral fat, leading to an overall reduction of BF%. Increased muscle mass in relation to fat weight leads to higher metabolism which enables a person to add muscle and lose fat simultaneously.

The best way to control fat long term is to add muscle. If you look at strict dieters/vegetarians, long distance runners, women, etc. they very easily add or always have higher amounts of subQ fat (flab). When their dieting or training is not strict, they add flab very quickly. Bodybuilders on the other hand, tend to add more visceral fat & H20 weight when off season or bulking, but easily maintain a level of "hardness" year around. Visceral fat is lost & gained very quickly & is much more controllable than sub Q fat.

To answer your question about bulking cycles, yes & no. Do cycles to add mass (eg test/EQ/dbol/tren or Test/Winny/Anavar/Tren---either one will help add muscle) but just eat clean. The trick is to change body compostion by adding LBM. Throwing in a clen/T3 cycle can accelerate the fat loss process, but the focus should be adding muscle if you feel you fit in the "skinny fat guy" mold. Any of us that picked up bodybuilder after the age of 28 will tell you that once we reached a certain level of muscularity, fat loss became significantly easier than when LBM was low.

 

[Stew Meat]

Int J Obes Relat Metab Disord 1995 Sep;19(9):614-24 Related Articles, Books, LinkOut


Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat

Lovejoy JC, Bray GA, Greeson CS, Klemperer M, Morris J, Partington C, Tulley R.

Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808-4124, USA.

OBJECTIVE: To compare the effects of testosterone enanthate (TE), anabolic steroid (AS) or placebo (PL) on regional fat distribution and health risk factors in obese middle-aged men undergoing weight loss by dietary means. DESIGN: Randomized, double-blind, placebo-controlled clinical trial, carried out for 9 months with primary assessments at 3 month intervals.

SUBJECTS: Thirty healthy, obese men, aged 40-60 years, with serum testosterone (T) levels in the low-normal range (2-5 ng/mL).

MAIN OUTCOME MEASURES:
Abdominal fat distribution and thigh muscle volume by CT scan, body composition by dual energy X-ray absorptiometry (DEXA), insulin sensitivity by the Minimal Model method, blood lipids, blood chemistry, blood pressure, thyroid hormones and urological parameters.

RESULTS:
After 3 months, there was a significantly greater decrease in subcutaneous (SQ) abdominal fat in the ASOX group compared to the TE and PL groups although body weight changes did not differ by treatment group. There was also a tendency for the ASOX group to exhibit greater losses in visceral fat, and the absolute level of visceral fat in this group was significantly lower at 3 months than in the TE and PL groups. There were significant main effects of treatment at 3 months on serum T and free T (increased in the TE group and decreased in the ASOX group) and on thyroid hormone parameters (T4 and T3 resin uptake significantly decreased in the ASOX group compared with the other two groups). There was a significant decrease in HDL-C, and increase in LDL-C in the ASOX group, which led to their being switched to the parenteral nandrolone decanoate (ASND) after 3 months. ASND had opposite effects on visceral fat from ASOX, producing a significant increase from 3 to 9 months while continuing to decrease SQ abdominal fat. ASND treatment also decreased thigh muscle area, while ASOX treatment increased high muscle. ASND reversed the effects of ASOX on lipoproteins and thyroid hormones. The previously reported effect of T to decrease visceral fat was not observed, in fact, visceral fat in the TE group increased slightly from 3 to 9 months, although SQ fat continued to decrease. Neither TE nor AS treatment resulted in any change in urologic parameters.

CONCLUSIONS:
Oral oxandrolone decreased SQ abdominal fat more than TE or weight loss alone and also tended to produce favorable changes in visceral fat. TE injections given every 2 weeks had similar effects to placebo on regional body fat. Most of the beneficial effects observed on metabolic and cardiovascular risk factors were due to weight loss per se. These results suggest that SQ and visceral abdominal fat can be independently modulated by androgens and that at least some anabolic steroids are capable of influencing abdominal fat.





-Stew

 

[Montecristo]

Stop wearing a black warlock patch!

 

[PimpnAintEasy]

Muscle gains without added visceral fat should and does increase the rate at which Sub Q is lost. TE gains tend to come with visceral fat increases, slowing the rate at which SubQ is lost. Ox & tren have been shown to lead to muscle gains without added visceral fat, which speeds up the total process. This is a physiological function more than a direct function of ox or tren. The direct relationship between ox & tren is added muscle without visceral fat gains.

 

[GLP]

Fina and dbal put me in the best shape of my life was 186 HARD. took 5 dbal a day and 140mg fin eod felt like a champ erevy time i worked out. That stack gave me better pumps that 1250mg test a week and made me look good the test bloated the shit out of me.

 

[Namu]

Guys, after reading this post I am very eager to get my hands on some yohimbe HCL. I too suffer from the dreaded belly fat that will not go away. I was quite a large adolescent and have been trying so hard over the past few years to rid my midsection of this STUFF but cannot seem to . Can someone lead me in the right direction for Yohimbe HCL via email?
Thanks
[email protected]